You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!
Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
Foster City, California
52 Week High
52 Week Low
The M&A surge: Is it rational exuberance or a frenzy before the market falls?
The M&A surge: Is it rational exuberance or a frenzy before the market falls? More The rise in equity markets and low funding costs encouraged chief executives
Dealmakers See $69 Billion of M&A in Year’s Busiest Weekend
(Bloomberg) -- A blockbuster Sunday of takeovers has bled into Monday for the fastest start to a week for global dealmaking this year. Companies led by Japanes
— per share
Expected Oct 22, After Hours
Gilead's shares rise after $21 billion deal for Immunomedics
(Reuters) - Shares of Gilead Sciences Inc <GILD.O> rose 3.2% on Monday, reversing their premarket losses as investors shrugged off concerns over the steep premi
Gilead Ramps Up Cancer Focus With $21 Billion Immunomedics Deal
(Bloomberg) -- Gilead Sciences Inc. agreed to acquire Immunomedics Inc. for about $21 billion, a substantial premium for the maker of a promising breast-cancer
Yahoo FinanceSep 14
Gilead Sciences to acquire Immunomedics in $21B deal
Gilead Sciences is set to acquire Immunomedics in a $21 billion dollar deal, which is expected to close in the fourth quarter of 2020. Dr. Behzad Aghazadeh, Imm
Gilead CEO: We're studying new ways to treat coronavirus with remdesivir outside of the hospital
Gilead Sciences CEO Daniel O'Day told CNBC on Monday the company is continuing to study new ways to use its coronavirus treatment remdesivir on patients, includ
Gilead bolsters cancer portfolio with $21 billion acquisition of Immunomedics
(Reuters) - Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining acces